Immunome (IMNM)

• Market cap: $2.03B
• 1 day: -0.89%
• 5 days: -2.5%
• 1 month: -10%
• 3 months: -12.03%
• 6 months: -23.72%
• Year to date: -13.98%
• 1 year: 87.74%
• 5 years: 5.6%
• 10 years: 33.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Employees: 177